Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 13;4(1):rkaa008.
doi: 10.1093/rap/rkaa008. eCollection 2020.

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

Yuta Yamaguchi  1 , Takayoshi Morita  1   2 , Atsushi Kumanogoh  1   2   3
Affiliations
Review

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

Yuta Yamaguchi et al. Rheumatol Adv Pract. .

Abstract

Objective: Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients with GIO.

Methods: A comprehensive systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PubMed, Web of Science and Google Scholar were used to search for original studies reported about BMD in patients with GIO treated with denosumab. In meta-analysis of BMD, the mean difference in the rate of change from baseline and the 95% CI were calculated using the random effects model. The mean differences in patients treated with denosumab were compared with those in patients treated with bisphosphonates.

Results: Out of 713 studies identified, seven studies met the selection criteria for the meta-analysis. At 6 and 12 months of denosumab therapy, increases in BMD were observed in the lumbar spine (2.99% [95% CI 2.71, 3.28] and 4.59% [95% CI 4.17, 5.01]), total hip (1.34% [95% CI 0.64, 2.04] and 2.16% [95% CI 2.05, 2.27]) and femoral neck (0.12% [95% CI -0.38, 0.62] and 1.55% [95% CI 0.45, 2.65]). Additionally, denosumab resulted in significant increases in BMD in the lumbar spine and femoral neck at 12 months compared with bisphosphonate therapy.

Conclusion: Patients with GIO experienced significant increases in BMD in response to treatment with denosumab that were detected in the lumbar spine, total hip and femoral neck at 12 months.

Keywords: anti-RANKL antibody; bone mineral density; denosumab; glucocorticoid-induced osteoporosis; meta-analysis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA flow diagram
Fig. 2
Fig. 2
Forrest plot: meta-analysis of BMD in the lumbar spine The rate of change of BMD at 6 (A) and 12 months (B) after the start of denosumab treatment was calculated using the random effects model. MRAW: raw (untransformed) means.
Fig. 3
Fig. 3
Forrest plot: meta-analysis of BMD in the total hip The rate of change of BMD at 6 (A) and 12 months (B) after the start of denosumab treatment was calculated using the random effects model. MRAW: raw (untransformed) means.
Fig. 4
Fig. 4
Forrest plot: meta-analysis of BMD in the femoral neck The change rate of BMD at 6 (A) and 12 months (B) after the start of denosumab treatment was calculated using the random effects model. MRAW: raw (untransformed) means.
Fig. 5
Fig. 5
Forrest plot: meta-analysis of BMD between denosumab and bisphosphonates The mean difference in BMD of the lumbar spine (A) and the femoral neck (B) was calculated using the random effects model. MD: mean difference.
See this image and copyright information in PMC

References

    1. Buckley L, Humphery MB.. Glucocorticoid-induced osteoporosis. N Eng J Med 2018;379:3547–56. - PubMed
    1. Liu X, Lei W, Wu A. et al. Effects of glucocorticoid on BMD, micro-architecture and biomechanics of cancellous and cortical bone mass in OVX rabbits. Med Eng Phys 2012;34:2–8. - PubMed
    1. van Staa T. P, Leufkens HGM, Cooper C.. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87. - PubMed
    1. Buckley L, Guyatt G, Fink HA.. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2018;70:949–50. - PubMed
    1. Graham G, Russell G.. Bisphosphonates: the first 40 years. Bone 2011;49:2–19. - PubMed

LinkOut - more resources